This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid010P It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid010P.html Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine. The full table of all monthly collections is: at house-of-papers.com PMC searches were done at moremed.org
PMC7313652 1. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
PMC7322813 6. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
PMC7300936 13. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
PMC7296193 18. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.
PMC7315014 20. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.
PMC7305916 27. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.
PMC7303568 33. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
PMC7313501 40. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine.
PMC7301831 55. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.
PMC7305057 74. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
{{tp|p=32581256|t=2020. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.|pdf=|usr=}} {{tp|p=32555446|t=2020. Overview of therapeutic drug research for COVID-19 in China.|pdf=|usr=}} {{tp|p=32544884|t=2020. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.|pdf=|usr=}} {{tp|p=32574894|t=2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.|pdf=|usr=}} {{tp|p=32583087|t=2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.|pdf=|usr=}} {{tp|p=32551892|t=2020. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=}} {{tp|p=32543882|t=2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.|pdf=|usr=}} {{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=}} {{tp|p=32575554|t=2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.|pdf=|usr=}} {{tp|p=32562705|t=2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.|pdf=|usr=}} {{tp|p=32557214|t=2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.|pdf=|usr=}} {{tp|p=32586336|t=2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.|pdf=|usr=}} {{tp|p=32554525|t=2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=}} {{tp|p=32572174|t=2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.|pdf=|usr=}} {{tp|p=32546835|t=2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?|pdf=|usr=}} {{tp|p=32557011|t=2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.|pdf=|usr=}} {{tp|p=32492407|t=2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.|pdf=|usr=}} {{tp|p=32546764|t=2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.|pdf=|usr=}} {{tp|p=32541865|t=2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.|pdf=|usr=}} {{tp|p=32588163|t=2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.|pdf=|usr=}} {{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=}} {{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=}} {{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=}} {{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=}} {{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=}} {{tp|p=32542396|t=2020. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.|pdf=|usr=}} {{tp|p=32593060|t=2020. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.|pdf=|usr=}} {{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=}} {{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=}} {{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=}} {{tp|p=32572376|t=2020. Literature-based review of the drugs used for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32578027|t=2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.|pdf=|usr=}} {{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=}} {{tp|p=32542964|t=2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology.|pdf=|usr=}} {{tp|p=32542893|t=2020. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.|pdf=|usr=}} {{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=}} {{tp|p=32592841|t=2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.|pdf=|usr=}} {{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=}} {{tp|p=32554953|t=2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?|pdf=|usr=}} {{tp|p=32592866|t=2020. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine.|pdf=|usr=}} {{tp|p=32574699|t=2020. Discovering small-molecule therapeutics against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32574697|t=2020. Current and future therapeutical approaches for COVID-19.|pdf=|usr=}} {{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=}} {{tp|p=32546018|t=2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.|pdf=|usr=}} {{tp|p=32578156|t=2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.|pdf=|usr=}} {{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=}} {{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=}} {{tp|p=32573433|t=2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.|pdf=|usr=}} {{tp|p=32569446|t=2020. Can artificial intelligence identify effective COVID-19 therapies?|pdf=|usr=}} {{tp|p=32579067|t=2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies.|pdf=|usr=}} {{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=}} {{tp|p=32548679|t=2020. Calling for an exponential escalation scheme in vaccine development for COVID-19.|pdf=|usr=}} {{tp|p=32591957|t=2020. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.|pdf=|usr=}} {{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=}} {{tp|p=32554535|t=2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.|pdf=|usr=}} {{tp|p=32589055|t=2020. Vesicular drug-delivery systems as theranostics in COVID-19.|pdf=|usr=}} {{tp|p=32564623|t=2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs.|pdf=|usr=}} {{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=}} {{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=}} {{tp|p=32544304|t=2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.|pdf=|usr=}} {{tp|p=32591003|t=2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.|pdf=|usr=}} {{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.|pdf=|usr=}} {{tp|p=32565362|t=2020. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues.|pdf=|usr=}} {{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=}} {{tp|p=32557206|t=2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.|pdf=|usr=}} {{tp|p=32582401|t=2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.|pdf=|usr=}} {{tp|p=32582400|t=2020. Steps towards COVID-19 suppression.|pdf=|usr=}} {{tp|p=32585611|t=2020. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.|pdf=|usr=}} {{tp|p=32565195|t=2020. Chloroquine cardiac effects and toxicity.A short update.|pdf=|usr=}} {{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=}} {{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=}} {{tp|p=32585194|t=2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.|pdf=|usr=}} {{tp|p=32592113|t=2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.|pdf=|usr=}} {{tp|p=32564289|t=2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.|pdf=|usr=}} {{tp|p=32572516|t=2020. Remdesivir bei Patienten mit COVID-19.|pdf=|usr=}} {{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=}}
110. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
{{tp|p=32583443|t=2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply.|pdf=|usr=}} {{tp|p=32578215|t=2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?|pdf=|usr=}} {{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=}} {{tp|p=32579022|t=2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?|pdf=|usr=}} {{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=}} {{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=}} {{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=}} {{tp|p=32539520|t=2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.|pdf=|usr=}} {{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=}} {{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=}} {{tp|p=32589165|t=2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.|pdf=|usr=}} {{tp|p=32551883|t=2020. COVID-19 and the Drug Repurposing Tsunami.|pdf=|usr=}} {{tp|p=32573724|t=2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.|pdf=|usr=}} {{tp|p=32559767|t=2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.|pdf=|usr=}} {{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=}} {{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=}} {{tp|p=32540958|t=2020. Hydroxychloroquine for covid-19: the end of the line?|pdf=|usr=}} {{tp|p=32556143|t=2020. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.|pdf=|usr=}} {{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=}} {{tp|p=32588427|t=2020. QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection.|pdf=|usr=}} {{tp|p=32589775|t=2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.|pdf=|usr=}} {{tp|p=32552642|t=2020. Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=}} {{tp|p=32562762|t=2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?|pdf=|usr=}} {{tp|p=32592507|t=2020. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.|pdf=|usr=}} {{tp|p=32588937|t=2020. Adjustments in analyses of vitamin D status, allowing for vitamin D determinants, for Covid-19 risks.|pdf=|usr=}} {{tp|p=32559771|t=2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.|pdf=|usr=}} {{tp|p=32588530|t=2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses.|pdf=|usr=}} {{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=}} {{tp|p=32543297|t=2020. Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!|pdf=|usr=}} {{tp|p=32574081|t=2020. Can nanotechnology help in the fight against COVID-19?|pdf=|usr=}} {{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=}} {{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=}} {{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=}} {{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=}} {{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=}}
PMC7323389 113. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.
PMC7297718 115. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
126. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
PMC7301049 128. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
PMC7304316 131. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
PMC7305501 136. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
137. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.
PMC7306734 157. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.
160. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.
PMC7301079 163. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.
PMC7323047 169. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.
{{tp|p=32557648|t=2020. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.|pdf=|usr=}} {{tp|p=32557541|t=2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=}} {{tp|p=32561274|t=2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.|pdf=|usr=}} {{tp|p=32567262|t=2020. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.|pdf=|usr=}} {{tp|p=32537956|t=2020. Uncertainty about the Efficacy of Remdesivir on COVID-19.|pdf=|usr=}} {{tp|p=32539378|t=2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.|pdf=|usr=}} {{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=}} {{tp|p=32588188|t=2020. Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"|pdf=|usr=}} {{tp|p=32565096|t=2020. Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use.|pdf=|usr=}} {{tp|p=32543196|t=2020. Repositioning of 8565 Existing Drugs for COVID-19.|pdf=|usr=}} {{tp|p=32586380|t=2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).|pdf=|usr=}} {{tp|p=32591466|t=2020. SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.|pdf=|usr=}} {{tp|p=32589146|t=2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir.|pdf=|usr=}} {{tp|p=32536150|t=2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.|pdf=|usr=}} {{tp|p=32553190|t=2020. Appropriate selection of convalescent plasma donors for COVID-19.|pdf=|usr=}} {{tp|p=32555367|t=2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.|pdf=|usr=}} {{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=}} {{tp|p=32553928|t=2020. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.|pdf=|usr=}} {{tp|p=32561657|t=2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?|pdf=|usr=}} {{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=}} {{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=}} {{tp|p=32558640|t=2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.|pdf=|usr=}} {{tp|p=32590819|t=2020. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study.|pdf=|usr=}} {{tp|p=32574789|t=2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).|pdf=|usr=}} {{tp|p=32570850|t=2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.|pdf=|usr=}} {{tp|p=32546125|t=2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.|pdf=|usr=}} {{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=}} {{tp|p=32551679|t=2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.|pdf=|usr=}} {{tp|p=32557405|t=2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.|pdf=|usr=}} {{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=}} {{tp|p=32572246|t=2020. Preclinical data from SARS-CoV-2 mRNA vaccine.|pdf=|usr=}} {{tp|p=32555401|t=2020. Optimizing safety surveillance for COVID-19 vaccines.|pdf=|usr=}} {{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=}} {{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=}} {{tp|p=32405159|t=2020. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?|pdf=|usr=}} {{tp|p=32564413|t=2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?|pdf=|usr=}} {{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32590099|t=2020. The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.|pdf=|usr=}} {{tp|p=32569819|t=2020. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients.|pdf=|usr=}} {{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=}} {{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=}} {{tp|p=32562826|t=2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.|pdf=|usr=}} {{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=}} {{tp|p=32592911|t=2020. Does PDT have potential in the treatment of COVID 19 patients?|pdf=|usr=}} {{tp|p=32585401|t=2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.|pdf=|usr=}} {{tp|p=32585400|t=2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.|pdf=|usr=}} {{tp|p=32561979|t=2020. Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules.|pdf=|usr=}} {{tp|p=32575476|t=2020. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.|pdf=|usr=}} {{tp|p=32569450|t=2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.|pdf=|usr=}} {{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=}} {{tp|p=32552811|t=2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.|pdf=|usr=}} {{tp|p=32558034|t=2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.|pdf=|usr=}} {{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=}} {{tp|p=32571730|t=2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.|pdf=|usr=}} {{tp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=}} {{tp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=}} {{tp|p=32558210|t=2020. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.|pdf=|usr=}}
170. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.
181. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).
184. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach.
185. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
187. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.
188. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.
193. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
194. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.
195. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.
199. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
216. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
222. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
{{tp|p=32568026|t=2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.|pdf=|usr=}} {{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=}} {{tp|p=32579043|t=2020. Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?|pdf=|usr=}} {{tp|p=32589449|t=2020. Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.|pdf=|usr=}} {{tp|p=32579021|t=2020. Meditation and Yoga Practices as Potential Adjunctive Treatment of SARS-CoV-2 Infection and COVID-19: A Brief Overview of Key Subjects.|pdf=|usr=}} {{tp|p=32591771|t=2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.|pdf=|usr=}} {{tp|p=32556272|t=2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.|pdf=|usr=}} {{tp|p=32586154|t=2020. Montelukast's ability to fight COVID-19 infection.|pdf=|usr=}} {{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=}} {{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=}} {{tp|p=32579064|t=2020. In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19.|pdf=|usr=}} {{tp|p=32579061|t=2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).|pdf=|usr=}} {{tp|p=32579059|t=2020. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.|pdf=|usr=}} {{tp|p=32573355|t=2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.|pdf=|usr=}} {{tp|p=32573351|t=2020. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach.|pdf=|usr=}} {{tp|p=32571168|t=2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.|pdf=|usr=}} {{tp|p=32568620|t=2020. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach.|pdf=|usr=}} {{tp|p=32568618|t=2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.|pdf=|usr=}} {{tp|p=32568613|t=2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.|pdf=|usr=}} {{tp|p=32568013|t=2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.|pdf=|usr=}} {{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=}} {{tp|p=32567995|t=2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.|pdf=|usr=}} {{tp|p=32567989|t=2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.|pdf=|usr=}} {{tp|p=32567979|t=2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.|pdf=|usr=}} {{tp|p=32567501|t=2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.|pdf=|usr=}} {{tp|p=32567487|t=2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.|pdf=|usr=}} {{tp|p=32568969|t=2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.|pdf=|usr=}} {{tp|p=32579707|t=2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19.|pdf=|usr=}} {{tp|p=32571115|t=2020. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.|pdf=|usr=}} {{tp|p=32538738|t=2020. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.|pdf=|usr=}} {{tp|p=32584243|t=2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History.|pdf=|usr=}} {{tp|p=32591393|t=2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.|pdf=|usr=}} {{tp|p=32559452|t=2020. Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?|pdf=|usr=}} {{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=}} {{tp|p=32546047|t=2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.|pdf=|usr=}} {{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=}} {{tp|p=32579258|t=2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32578354|t=2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.|pdf=|usr=}} {{tp|p=32554811|t=2020. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.|pdf=|usr=}} {{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=}} {{tp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=}} {{tp|p=32564047|t=2020. Chloroquine in controlling biological infections.|pdf=|usr=}} {{tp|p=32569363|t=2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.|pdf=|usr=}} {{tp|p=32584474|t=2020. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.|pdf=|usr=}} {{tp|p=32568376|t=2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.|pdf=|usr=}} {{tp|p=32556278|t=2020. Real-life experience of tocilizumab use in COVID-19 patients.|pdf=|usr=}} {{tp|p=32543892|t=2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.|pdf=|usr=}} {{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=}} {{tp|p=32585765|t=2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.|pdf=|usr=}} {{tp|p=32573990|t=2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.|pdf=|usr=}} {{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=}} {{tp|p=32591367|t=2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?|pdf=|usr=}} {{tp|p=32542847|t=2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.|pdf=|usr=}}
